Five things for pharma marketers to know: Tuesday, July 14, 2020
Pfizer, BioNTech vaccines fast tracked by FDA; Delayed routine care is causing another health crisis; Coronavirus antibodies may only last a few months.
Roundup
Five things for pharma marketers to know: Monday, July 13, 2020
WHO: Reinstating some lockdown measures may be necessary; Florida reports more than 15,000 cases in single day; Meredith’s POC head on serving Hispanic audiences.
Five things for pharma marketers to know: Friday, July 10, 2020
Drug prices continue to rise; CDC won’t change school reopening guidelines; WHO says indoor airborne transmission of COVID-19 can’t be ruled out.
Five things for pharma marketers to know: Thursday, July 9, 2020
Coronavirus cases in U.S. pass 3 million; Walgreens partners with VillageMD; Biogen submits Alzheimer’s drug for FDA approval.
Five things for pharma marketers to know: Wednesday, July 8, 2020
Novavax receives $1.6b for COVID-19 vaccine; Trump begins process of withdrawal from WHO; PPE shortages return as cases spike.
Five things for pharma marketers to know: Tuesday, July 7, 2020
Doctors urge WHO to acknowledge airborne transmission of COVID-19; FDA approves Becton Dickinson’s rapid antigen test; Webcast: Leverage machine learning, AI to improve trial recruitment.
Five things for pharma marketers to know: Monday, July 6, 2020
MM&M Move Together five-day fitness challenge; #CreateHealthEquity: Convince the world access to quality healthcare is a fundamental human right; MM&M Online Expo virtual event.
Five things for pharma marketers to know: Thursday, July 2, 2020
Pfizer, BioNTech coronavirus vaccine shows promise; Sherlock Biosciences to bring CRISPR COVID-19 test to doctor’s offices; Submit a cover design for MM&M’s Hall of Femme issue.
Five things for pharma marketers to know: Wednesday, July 1, 2020
FDA outlines conditions to approve coronavirus vaccine; Fauci warns daily COVID-19 cases could more than double in U.S.; Join the MM&M Move Together event.
Five things for pharma marketers to know: Tuesday, June 30, 2020
Gilead announces price for remdesivir; Bipartisan support of drug price legislation has waned; More states slow down reopening as COVID-19 cases rise.
Five things for pharma marketers to know: Monday, June 29, 2020
Justice Department asks Supreme Court to overturn ACA; States reverse reopening as virus cases climb; Submit creative to MM&M’s #CreateHealthEquity initiative.
Five things for pharma marketers to know: Friday, June 26, 2020
CDC changes populations at risk for severe COVID-19 illness; Texas pauses reopening as cases spike; CDC considers TikTok to educate young people about virus.
Five things for pharma marketers to know: Thursday, June 25, 2020
Judge rules hospitals, insurers must disclose some pricing; Remdesivir could be priced at $5,080; Bayer settles Roundup lawsuits.
Five things for pharma marketers to know: Wednesday, June 24, 2020
J&J loses bid to overturn baby powder ruling; Health officials testify before Congress on the COVID-19 response; Coronavirus cases hit new record highs in reopened states.
Five things for pharma marketers to know: Tuesday, June 23, 2020
Gilead to test inhaled version of remdesivir; Akili’s video game ADHD treatment could shape future digital therapeutics; Register to attend MM&M Convene Crisis Control on Thursday.
Want to read more?
Please login or register first to view this content.
